Table 1 Description of studies included in the final analysis

TOTAL

N = 97

REPORTS

N = 62

ONGOING STUDIES

N = 35

SOURCE

Publication year, n (%)

2002–2010

20 (20.6)

17 (27.4)

3 (8.6)

2011–2015

28 (28.9)

23 (37.1)

5 (14.3)

2016–2020

49 (50.5)

22 (35.5)

27 (77.1)

Source, n (%)

Bibliographic databases

70 (72.2)

62 (100.0)

8 (22.9)

Registers

27 (27.8)

0

27 (77.1)

SETTING

International study, n (%)

Yes

9 (9.3)

3 (4.8)

6 (17.1)

No

87 (89.7)

58 (93.6)

29 (82.9)

Unclear

1 (1.0)

1 (1.6)

0

Continent of study recruitment, n (%) ^a

North America

15 (15.5)

6 (9.7)

9 (25.7)

South America

1 (1.0)

1 (1.6)

0

Europe

26 (26.8)

12 (19.4)

14 (40.0)

Asia

53 (54.6)

39 (62.9)

14(40.0)

Africa

4 (4.1)

4 (6.5)

0

Oceania

1 (1.0)

0

1 (2.9)

Unclear

1 (1.0)

1 (1.6)

0

Number of centres, n (%)

1

72 (74.2)

53 (85.5)

19 (54.3)

2–5

14 (14.4)

5 (8.1)

9 (25.7)

> 5

9 (9.3)

2 (3.2)

7 (20.0)

Unclear

2 (2.1)

2 (3.2)

0

FUNDING

Funding body, n (%)

Public

43 (44.3)

13 (21.0)

30 (85.7)

Private

6 (6.2)

1 (1.6)

5 (14.3)

Both private and public

1 (1.0)

1 (1.6)

0

No specific funding

4 (4.1)

4 (6.5)

0

Not reported

43 (44.3)

43 (69.4)

0

DESIGN

Study type, n (%)

Comparative

32 (33.0)

15 (24.2)

17 (48.6)

Prospective cohort

64 (66.0)

46 (74.2)

18 (51.4)

Case series

1 (1.0)

1 (1.6)

0

PARTICIPANTS

Study population type, n (%)

Children

28 (28.9)

17 (27.4)

11 (31.4)

Adults

5 (5.1)

0

5 (14.3)

Both

63 (65.0)

44 (71.0)

19 (54.3)

Unclear

1 (1.0)

1 (1.6)

0

Included participant diseases, n (%) ^a

Simple lymphatic malformations

51 (52.6)

37 (59.7)

14 (40.0)

Simple venous malformations

52 (53.6)

37 (59.7)

15 (42.9)

Slow flow combined malformations including syndromic forms

21 (21.7)

10 (16.1)

11 (31.4)

Arteriovenous malformations

14 (14.4)

7 (11.3)

7 (20.0)

Rare vascular tumors

18 (18.6)

9 (14.5)

9 (25.7)

Several diseases

27 (27.8)

18 (29.0)

9 (25.7)

TOTAL

N = 97

STUDY STATUS

STUDY OBJECTIVE

REPORTS

N = 62

ONGOING STUDIES

N = 35

COMPARATIVE STUDIES

N = 32

NON-COMPARATIVE STUDIES

N = 65

INTERVENTION

Intervention type in the experimental group, n (%) ^a

Parenteral drugs

3 (3.1)

2 (3.2)

1 (2.9)

2 (6.3)

1 (1.5)

Enteral drugs

25 (25.8)

6 (9.7)

19 (54.3)

10 (31.3)

15 (23.1)

Topical drugs

5 (5.2)

0

5 (14.3)

3 (9.4)

2 (3.1)

Interventional radiology

61 (62.9)

52 (83.9)

9 (25.7)

15 (46.9)

46 (70.8)

Physiotherapy

3 (3.1)

2 (3.2)

1 (2.9)

2 (6.3)

1 (1.5)

Surgery

0

0

0

0

0

Combined treatment

14 (14.4)

10 (16.1)

4 (11.4)

0

0

SAMPLE SIZE

Planned sample size, n (%)

≤ 10^b

3 (3.1)

1 (1.6)

2 (5.7)

0

3 (4.6)

11–24

6 (6.2)

1 (1.6)

5 (14.3)

3 (9.4)

3 (4.6)

25–49

12 (12.4)

1 (1.6)

11 (31.4)

6 (18.8)

6 (9.2)

50–99

12 (12.4)

2 (3.2)

10 (28.6)

6 (18.8)

6 (9.2)

≥ 100

7 (7.2)

1 (1.6)

6 (17.1)

4 (12.5)

3 (4.6)

Not planned

57 (58.8)

56 (90.3)

1 (2.9)

13 (40.6)

44 (67.7)

Number of patients included

Median

27.5

27.5

NA

39.0

20.0

[Q1; Q3]

[15.0 ; 43.8]

[15.0 ; 43.8]

NA

[28.0 ; 89.5]

[13.5 ; 43.0]

Number of patients included, n (%)

≤ 10

5 (5.2)

5 (8.1)

NA

0

5 (7.7)

11–24

24 (24.7)

24 (38.7)

NA

2 (6.3)

22 (33.8)

25–49

18 (18.6)

18 (29.0)

NA

8 (25.0)

10 (15.4)

50–99

9 (9.3)

9 (14.5)

NA

2 (6.3)

7 (10.8)

≥ 100

6 (6.2)

6 (9.7)

NA

3 (9.4)

3 (4.6)

NA

35 (36.1)

35 (36.1)

NA

17 (53.1)

18 (27.7)